<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">farmaec</journal-id><journal-title-group><journal-title xml:lang="en">FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology</journal-title><trans-title-group xml:lang="ru"><trans-title>ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2070-4909</issn><issn pub-type="epub">2070-4933</issn><publisher><publisher-name>IRBIS LLC</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">farmaec-85</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Russian Studies</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Российские исследования</subject></subj-group></article-categories><title-group><article-title>АNALYSIS OF PSYCHOTROPIC DRUG CONSUPTION FOR SCHIZOPHRENIA TREATMENT IN DIFFERENT TYPE HOSPITALS</article-title><trans-title-group xml:lang="ru"><trans-title>Анализ объемов потребления психотропных лекарственных средств, применяемых для лечения шизофрении, в стационарах различного типа</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Носова</surname><given-names>П. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Nosova</surname><given-names>P. S.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Решетько</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Reshetko</surname><given-names>O. V.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ГБОУ ВПО «Саратовский государственный медицинский университет им. В.И. Разумовского» Минздрава России<country>Россия</country></aff><aff xml:lang="en">Saratov state medical university named after V.I. Razumovsky<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>20</day><month>05</month><year>2015</year></pub-date><volume>7</volume><issue>4</issue><fpage>11</fpage><lpage>15</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Nosova P.S., Reshetko O.V., 2015</copyright-statement><copyright-year>2015</copyright-year><copyright-holder xml:lang="ru">Носова П.С., Решетько О.В.</copyright-holder><copyright-holder xml:lang="en">Nosova P.S., Reshetko O.V.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmacoeconomics.ru/jour/article/view/85">https://www.pharmacoeconomics.ru/jour/article/view/85</self-uri><abstract><p>the goal of our research was to carry out an analysis of psychotropic drug utilization used for patients with schizophrenia in two (state and municipal) in-patient clinics during 2000 and 2010, using the DDD methodology. As the result, we found out that psychotropic drug utilization increased from 2000 to 2010 in both types of in-patient clinics. Consumption of second-generation antipsychotics increase in state clinic in 2010. And in the state clinic we can observe a favorable trend in the decrease of antidepressants and tranquilizers consumption.</p></abstract><trans-abstract xml:lang="ru"><p>открытое фармакоэпидемиологическое ретроспективное исследование потребления психотропных лекарственных средств, применяемых для лечения шизофрении, проводилось в 2000-2010 гг. Цель: целью данного исследования было проведение анализа объемов потребления психотропных лекарственных средств (ЛС), применявшихся для лечения параноидной шизофрении в двух стационарах разного типа в 2000 и 2010 гг. с помощью методики «определенных дневных доз». Материалы и методы: оценивались демографические данные пациентов, диагноз, синдром, тип течения заболевания, длительность госпитализации, возраст начала заболевания; названия нейролептиков (НЛ) и препаратов сопутствующей терапии с указанием режима их применения (доза, кратность, путь введения), с использованием методики «определенных дневных доз» (Defined Daily Doses – DDD). Также оценивались побочные эффекты психофармакотерапии и исход лечения. Результаты: обнаружено, что объемы потребления психотропных ЛС при стационарном лечении шизофрении выросли с 2000 по 2010 г., независимо от типа стационара. Объемы использования атипичных НЛ в 2010 г. выросли при снижении объемов потребления антидепрессантов и транквилизаторов.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>объемы потребления</kwd><kwd>определенные дневные дозы</kwd><kwd>шизофрения</kwd><kwd>нейролептики</kwd><kwd>психофармакотерапия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>drug consumption</kwd><kwd>defined daily doses</kwd><kwd>schizophrenia</kwd><kwd>antipsychotic</kwd><kwd>psychopharmacotherapy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Совещание представителей национальных центров фармаконадзора стран-участниц программы ВОЗ по международному мониторингу лекарственных средств. Безопасность лекарств и фармаконадзор. 2009; 1: 3-6.</mixed-citation><mixed-citation xml:lang="en">The meeting of representatives of national pharmacovigilance centers participating countries of the WHO International Drug Monitoring. Drug safety and pharmacovigilance. Bezopasnost' lekarstv i farmakonadzor. 2009; 1: 3-6.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Тиганов А.С. Эндогенные психические заболевания. [Электронный ресурс]. Online-библиотека Научного центра психического здоровья РАМН. 2005; режим доступа: http://www.psychiatry.ru/ lib/54/book/29.</mixed-citation><mixed-citation xml:lang="en">Tiganov A.S. Endogenous mental illness. [Electronic resource]. Online-Library Mental Health Research Center RAMS [Jendogennye psihicheskie zabolevanija. [Jelektronnyj resurs]. Online-biblioteka Nauchnogo centra psihicheskogo zdorov'ja RAMN]. 2005; http://www. psychiatry.ru/lib/54/book/29.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Andretta M., Ciuna A., Corbari L. et al. Impact of regulatory changes on firstand second-generation antipsychotic drug consumption and expenditure in Italy. Soc. Psychiatry Psychiatr. Epidemiol. 2005; 40: 72-77.</mixed-citation><mixed-citation xml:lang="en">Andretta M., Ciuna A., Corbari L. et al. Impact of regulatory changes on firstand second-generation antipsychotic drug consumption and expenditure in Italy. Soc. Psychiatry Psychiatr. Epidemiol. 2005; 40: 72-77.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Aparasu R.R., Bhatara V., Gupta S. US national trends in the use of antipsychotics. Ann. Clin. Psychiatry. 2005; 17: 147-152.</mixed-citation><mixed-citation xml:lang="en">Aparasu R.R., Bhatara V., Gupta S. US national trends in the use of antipsychotics. Ann. Clin. Psychiatry. 2005; 17: 147-152.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ayanian J.Z., Weissman J.S., Chasan-Taber S. Quality of care for two common illnesses in teaching and nonteaching hospitals. Health Aff (Millwood). 1998; 17: 194-205.</mixed-citation><mixed-citation xml:lang="en">Ayanian J.Z., Weissman J.S., Chasan-Taber S. Quality of care for two common illnesses in teaching and nonteaching hospitals. Health Aff (Millwood). 1998; 17: 194-205.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Clinical Guideline 1. Schizophrenia. Core interventions in the treatment and management of schizophrenia in primary and secondary care. National Institute for Clinical Excellence (NICE). 2002; http:// www.nice.org.uk/cat.asp?c=4.</mixed-citation><mixed-citation xml:lang="en">Clinical Guideline 1. Schizophrenia. Core interventions in the treatment and management of schizophrenia in primary and secondary care. National Institute for Clinical Excellence (NICE). 2002; http:// www.nice.org.uk/cat.asp?c=4.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">De Oliveira I.R., Juruena M.F. Treatment of psychosis: 30 years of progress. J. Clin. Pharm. Therap. 2006; 31: 523-530.</mixed-citation><mixed-citation xml:lang="en">De Oliveira I.R., Juruena M.F. Treatment of psychosis: 30 years of progress. J. Clin. Pharm. Therap. 2006; 31: 523-530.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Diatta T., Blazejewski S., Portier A. et al. Patterns and frequency of atypical antipsychotic prescribing in psychiatric medical centers: a cross-sectional national survey. Fund. and Clin. Pharmacology. 2007; 21: 371-378.</mixed-citation><mixed-citation xml:lang="en">Diatta T., Blazejewski S., Portier A. et al. Patterns and frequency of atypical antipsychotic prescribing in psychiatric medical centers: a crosssectional national survey. Fund. and Clin. Pharmacology. 2007; 21: 371-378.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Domino M.E., Swartz M.S. Who are the new users of antipsychotic medications. Psychiatric Services. 2008; 59; 507-514.</mixed-citation><mixed-citation xml:lang="en">Domino M.E., Swartz M.S. Who are the new users of antipsychotic medications. Psychiatric Services. 2008; 59; 507-514.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Duggan M. Do new prescription drugs pay for themselves? The case of second-generation antipsychotics. J. Health Economics. 2005; 24: 1-31.</mixed-citation><mixed-citation xml:lang="en">Duggan M. Do new prescription drug spay for themselves?The case of second-generation antipsychotics. J. Health Economics. 2005; 24: 1-31.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Falkai P., Wobrock P., Lieberman J. et al. World Federation of Societies of Biological Psychiatry (WFSBP) psychiatry guidelines for biological treatment of schizophrenia: Part 2. Long-treatment of Schizophrenia. World J. Biol. Psychiatry. 2006; 7: 5-40.</mixed-citation><mixed-citation xml:lang="en">Falkai P., Wobrock P., Lieberman J. et al. World Federation of Societies of Biological Psychiatry (WFSBP) psychiatry guidelines for biological treatment of schizophrenia: Part 2. Long-treatment of Schizophrenia. World J. Biol. Psychiatry. 2006; 7: 5-40.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Farley J.F., Cline R.R., Schommer J.C. et al. Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic therapy. Clin. Ther. 2008; 30: 1524-1539.</mixed-citation><mixed-citation xml:lang="en">Farley J.F., Cline R.R., Schommer J.C. et al. Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic therapy. Clin. Ther. 2008; 30: 1524-1539.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Gjerden P., Slordal l., Bramness J. Prescription persistence and safety of antipsychotic medication: a national registry-based 3-year follow-up. Eur. J. Clin. Pharmacol. 2010; 66: 911-917.</mixed-citation><mixed-citation xml:lang="en">Gjerden P., Slordal l., Bramness J. Prescription persistence and safety of antipsychotic medication: a national registry-based 3-year follow-up. Eur. J. Clin. Pharmacol. 2010; 66: 911-917.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Guidelines for ATC classification and DDD assignment. 2003. 15. Shahian D.M., Liu X., Meyer G.S. Comparing Teaching Versus Nonteaching Hospitals: The Association of Patient Characteristics With Teaching Intensity for Three Common Medical Conditions. Academic Medicine. 2014; 89: 94-106.</mixed-citation><mixed-citation xml:lang="en">Guidelines for ATC classification and DDD assignment. 2003.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Trifiro G., Spina E., Brignoli O. et al. Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999-2002. Eur. J. Clin. Pharmacol. 2005; 61: 47-53.</mixed-citation><mixed-citation xml:lang="en">Shahian D.M., Liu X., Meyer G.S. Comparing Teaching Versus Nonteaching Hospitals: The Association of Patient Characteristics With Teaching Intensity for Three Common Medical Conditions. Academic Medicine. 2014; 89: 94-106.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Trifiro G., Spina E., Brignoli O. et al. Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999-2002. Eur. J. Clin. Pharmacol. 2005; 61: 47-53.</mixed-citation><mixed-citation xml:lang="en">Trifiro G., Spina E., Brignoli O. et al. Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999-2002. Eur. J. Clin. Pharmacol. 2005; 61: 47-53.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
